Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women

AIDS

Volumn 17, Issue 8, 2003, Pages 1195-1199

  Kosel, Bradley W ^a,e   Beckerman, Karen P ^b   Hayashi, Sandra ^c   Homma, Masato ^d   Aweeka, Francesca T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GILEAD SCIENCES   (United States)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

HIV protease inhibitors; HIV 1; Indinavir; Nelfinavir; Pharmacokinetics; Pregnancy; Women

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450; HYDROCORTISONE; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SCREENING; DRUG USE; ENZYME ACTIVITY; EVALUATION; FEMALE; HORMONE DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEASUREMENT; METABOLISM; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; SECOND TRIMESTER PREGNANCY; STEADY STATE; THIRD TRIMESTER PREGNANCY; URINALYSIS; URINE LEVEL;

ADULT; FEMALE; GESTATIONAL AGE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYDROCORTISONE; INDINAVIR; NELFINAVIR; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; VIRAL LOAD;

EID: 0037867606     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305230-00011     Document Type: Article

References (26)

1. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173-1180.
2. Public Health Service. Recommendations for the use of antiretroviral drugs in pregnant women for maternal health and for reducing perinatal HIV-1 transmission in the United States. Washington, DC: US Public Health Service; 2000:November.
3. Shaffer N, Roongpisuthipong A, Siriwasin W, Chotpitayasunondh T, Chearskul S, Young NL, et al. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis 1999, 179:590-599.
4. Little BB. Pharmacokinetics during pregnancy: evidence-based maternal dose formulation. Obstet Gynecol 1999, 93:858-868.
5. Odagiri E, Ishiwatari N, Abe Y, Jibiki K, Adachi T, Demura R, et al. Hypercortisolism and the resistance to dexamethasone suppression during gestation. Endocrinol Jpn 1988, 35:685-690.
6. Krauer B, Krauer F, Hytten FE. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther 1980, 10:301-328.
7. Sperling RS, Roboz J, Dische R, Silides D, Holzman I, Jew E. Zidovudine pharmacokinetics during pregnancy. Am J Perinatol 1992, 9:247-249.
8. O'Sullivan MJ, Boyer PJ, Scott GB, Parks WP, Weller S, Blum MR, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993, 168:1510-1516.
9. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998, 178:1327-1333.
10. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1- infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis 1998, 178:368-374.
11. Wang Y, Livingston E, Patil S, McKinney RE, Bardeguez AD, Gandia J, et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999, 180:1536-1541.
12. Jayewardene AL, Kearney B, Stone JA, Gambertoglio JG, Aweeka FT. An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma. J Pharm Biomed Anal 2001, 25:309-317.
13. Homma M, Beckerman K, Hayashi S, Jayewardene AL, Oka K, Gambertoglio JG, et al. Liquid chromatographic determination of urinary 6 beta-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant women. J Pharm Biomed Anal 2000, 23:629-635.
14. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, et al. The increase in urinary excretion of 6-beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989, 28:373-387.
15. Ohnhaus EE, Breckenridge AM, Park BK. Urinary excretion of 6 beta-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 1989, 36:39-46.
16. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK. Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 1998, 63:617-622.
17. Saenger P. 6 Beta-hydroxycortisol in random urine samples as an indicator of enzyme induction. Clin Pharmacol Ther 1983, 34:818-821.
18. Saenger P, Forster E, Kream J. 6 Beta-hydroxycortisol: a noninvasive indicator of enzyme induction. J Clin Endocrinol Metab 1981, 52:381-384.
19. Ohkita C, Goto M. Increased 6-hydroxycortisol excretion in pregnant women: implication of drug-metabolizing enzyme induction. DICP-Ann Pharmacother 1990, 24:814-816.
20. Nau H, Kuhnz W, Egger HJ, Rating D, Helge H. Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics. Clin Pharmacokinet 1982, 7:508-543.
21. Otani K. Risk factors for the increased seizure frequency during pregnancy and puerperium. Folia Psychiatr Neurol Jpn 1985, 39:33-41.
22. Bologa M, Tang B, Klein J, Tesoro A, Koren G. Pregnancy-induced changes in drug metabolism in epileptic women. J Pharmacol Exp Ther 1991, 257:735-740.
23. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001, 45;1086-1093.
24. Acosta EP, Zorrilla C, van Dyke R, Bardeguez A, Smith E, Hughes M, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001, 2:460-465.
25. Lewis R, Tran J, Lillibridge J, Schultz-Smith M, Kerr B, Hsyu P. Pharmacokinetics of nelfinavir after once daily dosing in combination with mini-doses of ritonavir in healthy subjects. In XIII International Conference on AIDS. Durban, South Africa 2000 [abstract LbPeB7049].
26. Angel JB, Khaliq Y, Monpetit ML, Cameron DW, Gallicano K. An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy. AIDS 2001, 15:417-419.